Table 3.
Summary of short-term PDAT for surgically GCTB.
| Author | Year | Group | Case | Age (Year) |
Doses | Pre-D (Doses) |
Follow-Up (Month) |
LR% | Level |
|---|---|---|---|---|---|---|---|---|---|
| Liang, H. et al. [26] | 2022 | short course | 41 | 31.3 ± 10.6 | a | ≤3 | 30.3 ± 14.6 | 8.8 | III |
| conventional | 25 | 31.7 ± 10.7 | b | >3 | 28.1 ± 15.8 | 20.8 | |||
| Hindiskere, S. et al. [93] | 2020 | short course | 48 | 30 ± 6.1 | a | ≤3 | 37 ± 11.4 | 27 | III |
| conventional | 36 | 30 ± 6.3 | b | >3 | 64 ± 15.7 | 36 | |||
| Zhang, R. Z. et al. [94] | 2019 | short course | 11 | 38.1 | c | <6 | 30 (13–45) | 27.2 | IV |
Note: Pre-D preoperative denosumab; LR%: local recurrence rate.; a: 120 mg every 2 weeks for 1 or 2 months; b: 120 mg monthly for 3–6 months with additional doses on days 8 and 15; c: 120 mg denosumab monthly, with additional doses on days 8 and 15 of the first cycle, six doses in total.